Janssen’s results show Tremfya beats Cosentyx in late stage psoriasis study
Johnson & Johnson’s Janssen has announced their results from Phase III ECLIPSE study, which show superior long-term efficacy of Tremfya (guselkumab) compared with Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis. The data, which was published in The Lancet, showed a significantly higher proportion of Tremfya patients achieved a PASI 90 response at Week